Alkermes
preliminary results from a phase study of an receptor agonist in healthy participants and patients with narcolepsy or idiopathic hypersomnia | Alkermes
Company
Deck Type
Sector
Industry
Deck date
October 2023
Slide
13 of 27
Related slides by other companies
Xeris Biopharma
Investor Presentation
October 2022
topline results of phase study of | Xeris Biopharma
Xeris Biopharma
Investor Presentation
October 2022
phase study design | Xeris Biopharma
Aeglea BioTherapeutics
Investor Presentation
October 2023
combination programs summary wot | Aeglea BioTherapeutics
MindMed
Investor Presentation
June 2023
key milestones anticipated phase study initiation | MindMed
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Investor Presentation
October 2023
Results
July 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io